This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Disruptive Pharma Ab. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Tuulikki Lindmark: Innovator in Pharmaceutical Ingredients
Introduction
Tuulikki Lindmark is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug formulations. His work focuses on enhancing the efficacy and delivery of active pharmaceutical ingredients.
Latest Patents
Lindmark holds a patent for "Amorphous active pharmaceutical ingredients comprising substantially amorphous mesoporous magnesium carbonate." This patent describes a solid and substantially amorphous admixture that includes Sorafenib as the active pharmaceutical ingredient (API) and a particulate anhydrous and substantially amorphous mesoporous magnesium carbonate (MMC). The patent also outlines a method for manufacturing this admixture and an oral pharmaceutical formulation that incorporates it.
Career Highlights
Throughout his career, Tuulikki Lindmark has demonstrated a commitment to advancing pharmaceutical science. His innovative approaches have led to the development of new formulations that improve drug solubility and bioavailability. His work is recognized for its potential to enhance treatment options for patients.
Collaborations
Lindmark has collaborated with several professionals in the field, including Sara Frykstrand Ångström and Ottilia Arvén. These collaborations have contributed to the successful development of his patented technologies.
Conclusion
Tuulikki Lindmark is a distinguished inventor whose work in pharmaceutical ingredients has the potential to transform drug delivery systems. His innovative patent reflects his dedication to improving healthcare solutions.